The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Pharmacological bypass of NAD + salvage pathway protects neurons from chemotherapy-induced degeneration
Open accessAbstract
Significance: Axon degeneration is caused by multiple chemotherapeutic agents and is a hallmark of chemotherapy-induced peripheral neuropathy (CIPN). CIPN is associated with the loss of the essential metabolite nicotinamide adenine dinucleotide (NAD + ), a vital metabolite involved in energy homeostasis, but whether NAD + loss or the accumulation of an NAD + precursor, nicotinamide mononucleotide (NMN), is responsible for axon degeneration is controversial. We found that axon degeneration caused by vincristine, a widely used chemotherapeutic agent, could be ameliorated by forcing peripheral neurons to use an NAD + biosynthetic pathway that bypasses NMN formation. This strategy provides an approach for preventing CIPN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NMN may exacerbate axon degeneration in vitro induced by the chemotherapeutic agent vincristine”
From NAD+ in Brain Aging and Neurodegenerative Disorders (2019) · cites this paper as Liu et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cantó, C., Menzies, K. J., & Auwerx, J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.023 · Cited by 1,648
Bieganowski, P., & Brenner, C. (2004) · Cell · doi:10.1016/s0092-8674(04)00416-7 · Cited by 750
Self-citationChemotherapy‐induced peripheral neurotoxicity: A critical analysis
Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C. S.-Y., Friedlander, M. L., Cassidy, J., Koltzenburg, M., & Kiernan, M. C. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21204 · Cited by 745
dSarm/Sarm1 Is Required for Activation of an Injury-Induced Axon Death Pathway
Osterloh, J. M., Yang, J. H., Rooney, T. M., Fox, A. N., Adalbert, R., Powell, E. H., Sheehan, A. E., Avery, M. A., Hackett, R., Logan, M. A., et al. (2012) · Science · doi:10.1126/science.1223899 · Cited by 688
Absence of Wallerian Degeneration does not Hinder Regeneration in Peripheral Nerve
Lunn, E. R., Perry, V. H., Brown, M. C., Rosen, H., & Gordon, S. (1989) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1989.tb00771.x · Cited by 646
Wallerian degeneration: an emerging axon death pathway linking injury and disease
Conforti, L., Gilley, J., & Coleman, M. P. (2014) · Nature reviews. Neuroscience · doi:10.1038/nrn3680 · Cited by 630
Essuman, K., Summers, D. W., Sasaki, Y., Mao, X., DiAntonio, A., & Milbrandt, J. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.022 · Cited by 619
Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene
Mack, T. G. A., Reiner, M., Beirowski, B., Mi, W., Emanuelli, M., Wagner, D., Thomson, D., Gillingwater, T., Court, F., Conforti, L., et al. (2001) · Nature Neuroscience · doi:10.1038/nn770 · Cited by 611
SARM1 activation triggers axon degeneration locally via NAD + destruction
Gerdts, J., Brace, E. J., Sasaki, Y., DiAntonio, A., & Milbrandt, J. (2015) · Science · doi:10.1126/science.1258366 · Cited by 593
REVERSIBLE ENZYMATIC SYNTHESIS OF DIPHOSPHOPYRIDINE NUCLEOTIDE AND INORGANIC PYROPHOSPHATE
Kornberg, A. (1950) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)56513-3 · Cited by 503
Grisold, W., Cavaletti, G., & Windebank, A. J. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos203 · Cited by 487
Endogenous Nmnat2 Is an Essential Survival Factor for Maintenance of Healthy Axons
Gilley, J., & Coleman, M. P. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000300 · Cited by 472
Biosensor reveals multiple sources for mitochondrial NAD +
Cambronne, X. A., Stewart, M. L., Kim, D., Jones-Brunette, A. M., Morgan, R. K., Farrens, D. L., Cohen, M. S., & Goodman, R. H. (2016) · Science · doi:10.1126/science.aad5168 · Cited by 407
Self-citationSarm1-Mediated Axon Degeneration Requires Both SAM and TIR Interactions
Gerdts, J., Summers, D. W., Sasaki, Y., DiAntonio, A., & Milbrandt, J. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.1197-13.2013 · Cited by 367
Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy
Diguet, N., Trammell, S. A. J., Tannous, C., Deloux, R., Piquereau, J., Mougenot, N., Gouge, A., Gressette, M., Manoury, B., Blanc, J., et al. (2018) · Circulation · doi:10.1161/circulationaha.116.026099 · Cited by 358
Self-citationA local mechanism mediates NAD-dependent protection of axon degeneration
Wang, J., Zhai, Q., Chen, Y., Lin, E., Gu, W., McBurney, M. W., & He, Z. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200504028 · Cited by 352
Pathways and Subcellular Compartmentation of NAD Biosynthesis in Human Cells
Nikiforov, A., Dölle, C., Niere, M., & Ziegler, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.213298 · Cited by 326
Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice
Trammell, S. A. J., Weidemann, B. J., Chadda, A., Yorek, M. S., Holmes, A., Coppey, L. J., Obrosov, A., Kardon, R. H., Yorek, M. A., & Brenner, C. (2016) · Scientific Reports · doi:10.1038/srep26933 · Cited by 301 · cited 1×
“NR, commonly used to prevent conditions associated with NAD loss (20, 25, 26), protected against the vincristine-induced decrease in NAD, but generated even higher levels of NMN.”
BackgroundSelf-citationSasaki, Y., Araki, T., & Milbrandt, J. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2320-06.2006 · Cited by 269
A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration
Di Stefano, M., Nascimento-Ferreira, I., Orsomando, G., Mori, V, Gilley, J., Brown, R., Janeckova, L., Vargas, M. E., Worrell, L. A., Loreto, A., et al. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.164 · Cited by 246
TARGETED, LCMS-BASED METABOLOMICS FOR QUANTITATIVE MEASUREMENT OF NAD + METABOLITES
Trammell, S. A. J., & Brenner, C. (2013) · Computational and Structural Biotechnology Journal · doi:10.5936/csbj.201301012 · Cited by 193
Self-citationAn 85-kb tandem triplication in the slow Wallerian degeneration ( Wld s ) mouse
Coleman, M. P., Conforti, L., Buckmaster, E. A., Tarlton, A., Ewing, R. M., Brown, M. C., Lyon, M. F., & Perry, V. H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.9985 · Cited by 193
NMNAT1 inhibits axon degeneration via blockade of SARM1-mediated NAD+ depletion
Sasaki, Y., Nakagawa, T., Mao, X., DiAntonio, A., & Milbrandt, J. (2016) · eLife · doi:10.7554/elife.19749 · Cited by 192
Henninger, N., Bouley, J., Şıkoğlu, E. M., An, J., Moore, C. M., King, J. A., Bowser, R. P., Freeman, M. R., & Brown, R. H. (2016) · Brain · doi:10.1093/brain/aww001 · Cited by 189
Nicotinamide Riboside Kinase Structures Reveal New Pathways to NAD+
Tempel, W., Rabeh, W. M., Bogan, K. L., Belenky, P. A., Wójcik, M., Seidle, H. F., Nedyalkova, L., Yang, T., Sauve, A. A., Park, H.-W., et al. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050263 · Cited by 163
Self-citationStefano, M. D., Loreto, A., Orsomando, G., Mori, V., Zamporlini, F., Hulse, R. P., Webster, J., Donaldson, L. F., Gering, M., Raffaelli, N., et al. (2017) · Current Biology · doi:10.1016/j.cub.2017.01.070 · Cited by 95
Vaur, P., Brugg, B., Mericskay, M., Li, Z., Schmidt, M. S., Vivien, D., Orset, C., Jacotot, E. D., Brenner, C., & Duplus, E. (2017) · The FASEB Journal · doi:10.1096/fj.201700221rr · Cited by 89
Self-citationKornberg, A. (1948) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)57167-2 · Cited by 81
Bieganowski, P., Pace, H. C., & Brenner, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302257200 · Cited by 73
Self-citation
Cited by
Sorted by citations
NAD+ in Brain Aging and Neurodegenerative Disorders
Lautrup, S., Sinclair, D. A., Mattson, M. P., & Fang, E. F. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.001 · Cited by 790
Programmed axon degeneration: from mouse to mechanism to medicine
Coleman, M. P., & Höke, A. (2020) · Nature reviews. Neuroscience · doi:10.1038/s41583-020-0269-3 · Cited by 329
SARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger axon degeneration
Figley, M. D., Gu, W., Nanson, J. D., Shi, Y., Sasaki, Y., Cunnea, K., Malde, A. K., Jia, X., Luo, Z., Saikot, F. K., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.02.009 · Cited by 324
Niacin in the Central Nervous System: An Update of Biological Aspects and Clinical Applications
Gasperi, V., Sibilano, M., Savini, I., & Catani, M. V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040974 · Cited by 286
Tribble, J. R., Otmani, A., Sun, S., Ellis, S. A., Cimaglia, G., Vohra, R., Jöe, M., Lardner, E., Venkataraman, A. P., Domínguez‐Vicent, A., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101988 · Cited by 236
Metadata
- Authors
- Liu, H.-W., Smith, C. B., Schmidt, M. S., Cambronne, X. A., Cohen, M. S., Migaud, M. E., Brenner, C., & Goodman, R. H.
- Affiliations
- Oregon Health & Science University (US)
- University of Iowa (US)
- University of South Alabama (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2018-09-26
- Volume
- 115
- Issue
- 42
- Pages
- 10654-10659
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC6196523
- OpenAlex
- W2894340007
- Cited by
- 105
- References
- 29
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 9 · 2023: 10 · 2022: 16 · 2021: 23 · 2020: 23 · 2019: 15
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | National Institutes of Health (1R01AG055431-01, DP2GM126897)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Keywords
- chemotherapy-induced peripheral neuropathy, NAD+ salvage pathway, nicotinamide mononucleotide, NAD biosynthesis, axonal degeneration, vincristine, peripheral neurons, neuroprotection
- MeSH terms
- Acrylamides, Animals, Antineoplastic Agents, Phytogenic, Drug Combinations, Francisella tularensis, Ganglia, Spinal, NAD, Nerve Degeneration, Neurons, Niacinamide, Nicotinamide Mononucleotide, Piperidines, Pyridinium Compounds, Vincristine, Nicotinamide Phosphoribosyltransferase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
